Triall — Advancing medical research through blockchain technology

Since the introduction of smart contracts, it has become evidently clear that blockchain technology will have a notable impact on the future of finance.

That being said, it’s important to acknowledge that the use of blockchain technology is appealing to other sectors that also rely heavily on data management. This includes the medical industry, as better record keeping can offer better transparency, security, trackability, and efficiency in everyday tasks. The tracking of an individuals’ personal medical history allows doctors to treat patients effectively and accurately, especially when time is of the essence.

However, due to the disconnection of data management between clinics, medical sites (e.g x-ray facilities), and hospitals, records kept even for individual patients often are fragmented and scattered throughout various networks. As a result, transferring key data files can be slow and at times require manual intervention, which can lead to human error. This becomes even more problematic for studies on a much larger scale, such as clinical trials.

At the forefront of solving this problem of this is Triall — a digital platform that bridges the gap between the need for blockchain technology and clinical research through innovative software solutions.

In a nutshell, Triall aims to lower the chances of errors and fraud, while reducing complexity in clinical trials. It also enables secure and efficient connections between the many isolated systems and parties involved in clinical research.

This is why our team at Phoenix are excited about investing in Triall, and what Triall will offer for the blockchain community, and the medical research sector.

The novel applications that Triall will offer will ultimately accelerate the process of bringing effective and efficacious treatments to the market for disorders, diseases, and infections such as COVID-19.

Triall will feature a two token system consisting of $TRL and $T-CRED.

The first token, $TRL, will be listed on centralized and decentralized exchanges, and will be needed to purchase the Triall utility token, $T-CRED, through a smart contract.

Since customers will need $T-CRED as payment for using the applications on the Triall platform, the value of $T-CRED is at a set, predictable rate.

Interestingly, the $TRL tokens used to create $T-CRED will be taken out of circulation. And over time, the T-CRED collected by as payment from Triall will be eventually converted back to $TRL, at a conversion rate 2.5% lower than the initial rate, making $TRL a deflationary asset.

We hope the world of DeFi will truly appreciate what Triall will bring to the world, and we wish them the best of luck in launching their token in September.

For more information:

Website: https://www.triall.io/

Telegram: https://t.me/triallcommunity

Bonus — See the potentiality of how blockchain technology can change medical research published in a prestigious scientific journal- Science, from Dr. Linda H.M van de Burgwall, CFO of Triall.

https://science.sciencemag.org/content/368/6492/719.long

How $TRL and $T-CRED works: https://www.youtube.com/watch?v=TljDkPA_FCQ